Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Post by Smokey1958on Jan 12, 2022 11:50am
318 Views
Post# 34308399

Reason(s) For Clinical Trials

Reason(s) For Clinical TrialsThroughout the pandemic companies that have produced a rapid antigen test and applied for an EUA had at least 2 FDA hurdles. The first was to supply test data to demonstrate the device worked (which included no cross reactivity issues) and could be used in a clinical setting and/or by health care professionals in a public setting. That would represent their first submission for approval. Months later (over the last year anyway) was a second submission for application for at home use.

While purely speculation on my part it appears THRM either through its summary of invitro tests and/or its trials in Brazil  paased the first test ...with the exception of the cross reactivity tests which would have been carried out sometime after Rob's second last interview. This is when he mentioned this. It also seems that because of timing, the FDA "packaged" the application process into one ...to include the at home clinical trials as part of one whole submission. This is the critical piece for me in believing that unless something went horribly wrong with individuals being able to take their own saliva samples that an FDA EUA has never been a matter of if but instead of when it would be provided.

It makes no sense to have otherwise carried this on for months!!!
<< Previous
Bullboard Posts
Next >>